Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn completes enrollment in Phase IIa erectile dysfunction trial
The Zoraxel Phase IIa trial is a double blind, placebo-controlled, dose ranging study conducted at three US study sites in up to 40 male subjects ages 18 to
The Zoraxel Phase IIa trial is a double blind, placebo-controlled, dose ranging study conducted at three US study sites in up to 40 male subjects ages 18 to
Quarterly Results: Instrument, reagent disc and hematology reagent revenues increased by an aggregate of $1.0 million, or 4%, for the quarter ended December 31, 2008, over the same
The limited launch of these systems in Europe marks St Jude Medical’s first products in the deep brain stimulation (DBS) systems market. The Libra DBS systems function in
The payment has been triggered by the successful transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403. The
A total of 214 patients have enrolled two months ahead of schedule in the clinical study of Urgent PC versus sham effectiveness in treatment of overactive bladder symptoms
David Brennan, chief executive officer, said: “AstraZeneca has delivered a robust performance in an increasingly challenging market environment. I am particularly pleased with our continued success in globalising
“SurModics achieved record revenue and earnings for the first quarter of fiscal 2009, driven primarily by the recognition of previously deferred revenue, which was triggered by Merck’s termination
Revenue for the fourth quarter was $78.6 million, as compared to total revenue of $107.6 million in the fourth quarter of 2007. For the fourth quarter of 2008,
These agreements stop all current litigation between the two parties in the fields of interventional cardiology and endovascular repair. All the disputes involved intellectual property. The stand-down agreements
Data obtained from animal studies have demonstrated that Ampakine compounds can specifically stimulate breathing by activating regions in the brain stem. In 2008, Cortex announced positive results of